Purpose Are existing systematic reviews of interventions for age-related macular
degeneration incorporated into clinical practice guidelines? Design High-quality systematic …

Background To investigate whether treatment as required 'pro re nata'(PRN) versus regular
monthly treatment regimens lead to differences in outcomes in neovascular age-related …

Purpose To examine visual outcomes and recurrence rates in patients with choroidal
neovascularization (CNV) resulting from neovascular age-related macular degeneration …

Age‐related macular degeneration (AMD) is the main cause of visual impairment in
developed countries. Several improvements in the visualization of posterior segment of the …

Objective To determine the effectiveness of bevacizumab step therapy for neovascular age-
related macular degeneration (nAMD) in routine clinical practice. Methods In this …

Purpose Wet age‐related macular degeneration (AMD) is the leading cause of blindness
worldwide, which can be treated with regular intraocular anti‐vascular endothelial growth …

Importance Age-related macular degeneration (AMD) is a leading cause of vision
impairment. It is imperative that AMD care is timely, appropriate, and evidence-based. It is …

Purpose: To determine the dose–response characteristics of the antivascular endothelial
growth factor agents ranibizumab and aflibercept in neovascular age-related macular …

Background & Aim: Photosensitizers are key molecules used in photodynamic cancer
therapy (PDT), which is an effective therapeutic modality option for several diseases and …

Background: Age-related macular degeneration (AMD) is the leading cause of vision loss in
people over 60 years of age. Despite research, the causes of AMD remain unclear. Matrix …